KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
|
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 07期
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [21] PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER
    Hwang, Deok Won
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1075 - S1075
  • [22] Surviving expression as a prognostic factor in non-small cell lung cancer
    Peroukides, S.
    Alexopoulos, A.
    Christopoulos, Chr
    LUNG CANCER, 2007, 55 : S16 - S16
  • [23] Lymphopenia: Is it a prognostic factor in metastatic non-small cell lung cancer?
    El Mekkeoui, Zineb Benbrahim
    Arifi, Samia
    Amaadour, Lamiae
    Abda, Naima
    Nejjari, Chakib
    Nawfel, Mellas
    El Mesbahi, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] PTPRH Hypomethylation as a Prognostic Factor in Non-Small Cell Lung Cancer
    Sato, Takashi
    Soejima, Kenzo
    Arai, Eri
    Hamamoto, Junko
    Yasuda, Hiroyuki
    Arai, Daisuke
    Ishioka, Kota
    Ohgino, Keiko
    Naoki, Katsuhiko
    Kohno, Takashi
    Tsuta, Koji
    Watanabe, Shun-Ichi
    Kanai, Yae
    Betsuyaku, Tomoko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S722 - S722
  • [25] The angiogenesis patterns as a prognostic factor in non-small cell lung cancer
    Giatromanolaki, A
    3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 53 - 57
  • [26] Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer
    Ban, Wooho
    Lee, Jong Min
    Ha, Jick Hwan
    Yeo, Chang Dong
    Kang, Hyeon Hui
    Rhee, Chin Kook
    Moon, Hwa Sik
    Lee, Sang Haak
    YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1063 - 1069
  • [27] Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
    Ricciuti, Biagio
    Leonardi, Giulia Costanza
    Metro, Giulio
    Grignani, Francesco
    Paglialunga, Luca
    Bellezza, Guido
    Baglivo, Sara
    Mencaroni, Clelia
    Baldi, Alice
    Zicari, Daniela
    Crino, Lucio
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (01) : 53 - 68
  • [28] A Paradigm Shift for Resectable Non-Small Cell Lung Cancer
    Isla, Dolores
    Majem, Margarita
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (12): : 792 - 793
  • [29] Adjuvant treatment for resectable non-small cell lung cancer
    Lim, Jeong Uk
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (03): : 173 - 179
  • [30] Immunotherapy in surgically resectable non-small cell lung cancer
    Owen, Dwight
    Chaft, Jamie E.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S404 - S411